GENERAL ENQUIRIES: Tel: + 27 12 841 2911 | Email: callcentre@csir.co.za

Browsing by Author "Swai, HS"

Sort by: Order: Results:

  • Semete, B; Booysen, L; Kalombo, Lonji; Ramalapa, B; Hayeshi, R; Swai, HS (Elsevier, 2012-03)
    The surface of nanoparticles is often functionalised with polymeric surfactants, in order to increase systemic circulation time. This has been investigated mainly for intravenously administered nanoparticles. This study ...
  • Semete, B; Booysen, L; Lemmer, Yolandy; Kalombo, Lonji; Katata, L; Verschoor, J; Swai, HS (Elsevier, 2010-10)
    The remarkable physicochemical properties of particles in the nanometer range have been proven to address many challenges in the field of science. However, the possible toxic effects of these particles have raised some ...
  • Booysen, LLIJ; Kalombo, Lonji; Brooks, E; Hansen, R; Gilliland, J; Gruppo, V; Lungenhofer, P; Semete-Makokotlela, Boitumelo; Swai, HS; Kotze, AF; Lenaerts, A; du Plessis, LH (Elsevier, 2013-02)
    Poly-(dl-lactic-co-glycolic) acid (PLGA) nanoparticles were prepared by a double emulsion solvent evaporation spray-drying technique and coated with polyethylene glycol (PEG 1% v/v). The PLGA nanoparticles had a small size ...
  • Lemmer, Yolandy; Semete, B; Kalombo, Lonji; Ramalapa, B; Jones, AT; Swai, HS; Verschoor, JA (CSIR, 2010-09-01)
    Challenges in treatment of Tuberculosis (TB) include non-specific localisation of the drugs which results in too low concentrations of the drugs reaching the target site of infection, thus leading to reduced effectiveness. ...
  • Lemmer, Yolandy; Kalombo, Lonji; Pietersen, R-D; Jones, AT; Semete-Makokotlela, Boitumelo; Van Wyngaardt, S; Ramalapa, BE; Stoltz, A; Baker, B; Verschoor, JA; Swai, HS; De Chastellier, C (Elsevier, 2015-06)
    The appearance of drug-resistant strains of Mycobacterium tuberculosis (Mtb) poses a great challenge to the development of novel treatment programmes to combat tuberculosis. Since innovative nanotechnologies might alleviate ...
  • Swai, HS (2012-10)
    The author is the principal investigator of the TB Nano drug delivery project which is now going through pre-clinical trials with exciting results, and in this presentation the insights based on the case study will be shared.
  • Nkabinde, LA; Shoba-Zikhali, LN; Semete-Makokotlela, Boitumelo; Kalombo, Lonji; Swai, HS; Hayeshi, R; Naicker, B; Hillie, TK; Hamman, JH (Bentham Science Publishers, 2012-07)
    Many drug delivery systems have indicated improvement in delivery of various drug molecules and among these biodegradable and biocompatible polymers such as poly(D,L-lactide-co-glycolide) (PLGA) have been shown to enhance ...
  • Semete, B; Kalombo, Lonji; Katata, L; Chelule, P; Booysen, L; Lemmer, Yolandy; Naidoo, S; Ramalapa, B; Hayeshi, R; Swai, HS (Taylor & Francis, 2012-03)
    Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single ...
  • Lemmer, Yolandy; Semete, B; Booysen, L; Kalombo, Lonji; Katata, L; Jones, AT; Alexander, C; Khati, M; Swai, HS; Verschoor, JA (2010-06)
    South Africa currently has the highest incidence of TB per 100000 (358 per 100000) people in the world. In 2007 alone 112000 people died of TB in South Africa, of which 94 000 (72%) were co-infected with HIV. Although TB ...